SEC Comment Letter 0000000000-24-012705 to Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc.
Date: Nov. 18, 2024 · CIK: 0001367644 · Accession: 0000000000-24-012705
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283150
Letter
November 18, 2024 Richard Lindahl Executive Vice President, Chief Financial Officer and Treasurer Emergent BioSolutions Inc. 300 Professional Drive Gaithersburg, Maryland 20879 Re:Emergent BioSolutions Inc. Registration Statement on Form S-1 Filed November 12, 2024 File No. 333-283150 Dear Richard Lindahl: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Matthew Franker
Show Raw Text
November 18, 2024
Richard Lindahl
Executive Vice President, Chief Financial Officer and Treasurer
Emergent BioSolutions Inc.
300 Professional Drive
Gaithersburg, Maryland 20879
Re:Emergent BioSolutions Inc.
Registration Statement on Form S-1
Filed November 12, 2024
File No. 333-283150
Dear Richard Lindahl:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Matthew Franker